Cargando…
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
BACKGROUND: This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor−related protein (GITR), in pat...
Autores principales: | Tran, Ben, Carvajal, Richard D., Marabelle, Aurelien, Patel, Sandip Pravin, LoRusso, Patricia M., Rasmussen, Erik, Juan, Gloria, Upreti, Vijay V., Beers, Courtney, Ngarmchamnanrith, Gataree, Schöffski, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156919/ https://www.ncbi.nlm.nih.gov/pubmed/30253804 http://dx.doi.org/10.1186/s40425-018-0407-x |
Ejemplares similares
-
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
por: Hong, David S., et al.
Publicado: (2015) -
Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro
por: Amouzadeh, Hamid R., et al.
Publicado: (2019) -
Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro
por: Yamada, Reiko, et al.
Publicado: (2013) -
The decay scheme of $^{228}$Fr and $K=0$ bands in $^{228}$Ra
por: Ruchowska, E, et al.
Publicado: (1982) -
Comparison of AMG 416 and cinacalcet in rodent models of uremia
por: Walter, Sarah, et al.
Publicado: (2014)